ClinicalTrials.gg
Status unknownNCT05824897Updated Apr 24, 2023

The Cohort Study of the Correlation Between Serum 25(OH)D Level and Pregnancy Outcome

An observational study in Vitamin D Deficiency, Recurrent Miscarriage and Pregnancy Related, sponsored by Aimin Zhao. Status unknown at 1 site in China. Open to female participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-24.

Sponsored by Aimin Zhao · Observational

How we know

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
171
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Vitamin D Deficiency with a site in China — 3 open to participants now, 3 under way, none of them phase 3. Vitamin D Deficiency · China.

Planned enrollment
7th of 10
171 · median 193
Started
2022
with 2 others
Observational
10 of 28
2 open now
Registered
24th of 28
by date
Lead sponsor
1 of 28
Aimin Zhao

Among the 28 studies in Vitamin D Deficiency with a site in China, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2022, is one of 10 observational ones, and was the 24th registered.

Vitamin D Deficiency

800 studies on the registry are indexed under Vitamin D Deficiency; 60 are open to participants now.

Browse Vitamin D Deficiency studies →

Open to participants now

3 of the 28 studies in Vitamin D Deficiency with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Vitamin D Deficiency studies recruiting now, 16 (43%) set no upper age limit and 18 (49%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 20 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Vitamin D Deficiency with a site in China, or all of them as a file.
02

Study summary

The objective of this single-center prospective observational study is to clarify the trend of maternal serum 25(OH)D levels before pregnancy and during pregnancy, and to explore the correlation between serum 25(OH)D levels and subsequent pregnancy outcomes of patients with abortion, so as to provide certain scientific evidence for finding the optimal serum level of 25(OH)D and optimal vitamin D supplementation to maintain a healthy pregnancy.

Read the detailed description

Women of reproductive age who meet the inclusion criteria are recruited from the outpatient department of Renji Hospital from November 2022 to December 2023. Subjects fill in the basic information at the outpatient clinic. After being included in the study, peripheral blood is collected before and during the first trimester (\< 10 weeks), second trimester (22-24 weeks) and third trimester (32 weeks) to detect 25(OH)D, calcium, phosphorus and PTH levels. B-ultrasound examination is performed before pregnancy to record endometrial thickness, endometrial hemodynamic index (PI, RI and S/D) and uterine arterial hemodynamic index (PI, RI and S/D) during the luteal phase. Data are comprehensively analyzed through questionnaire form filling, laboratory examination, and clinical information records including pregnancy outcomes (final live birth rate, cesarean section rate, pregnancy loss rate, etc.), obstetric complications, and neonatal delivery information.

03

Conditions studied

  • Vitamin D Deficiency
  • Recurrent Miscarriage
  • Pregnancy Related

Keywords

  • vitamin D
  • pregnancy
  • recurrent spontaneous abortion
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women of childbearing age who are ready to become pregnant or already pregnant.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥20 years old
  • The chromosome karyotype of the couple is normal
  • Color ultrasound examination results indicated that there was no organic disease related to reproductive tract
  • No serious complications of surgery and medicine
  • Agree and voluntarily sign

Exclusion criteria

Exclusion Criteria:

  • There are to pregnancy
  • the initiative to give up pregnancy
  • Severe medical and surgical complications, for example, liver disease was defined as serum [ALT] or aspartic aminotransferase [AST]>3 x upper normal limit [] after repeated testing
  • Concomitant malignant tumor, malignant tumor developed in the last 5 years (except for the skin squamous basal cell carcinoma that has been removed and considered cured). Subjects who developed malignant tumors more than 5 years ago should provide evidence of remission or cure. Subjects with a history of cervical cancer were eligible if they could demonstrate that their cervical cancer had been cone removed or cured within the past 3 years
  • Known (HIV) positive and/or surface antigen or virus antibody positive at screening visit
  • With a history of chronic infections such as mycoplasma, chlamydia, cryptococcus, and invasive fungal infections should be discussed with the principal investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
171 participants (estimated)
Patient registry
No

Interventions

  • OtherSerum levels of vitamin D

    Subjects in this study are grouped according to baseline serum levels of 25(OH)D. The serum level of total 25(OH)D ≥30ng/ml (75nM) is sufficient, 20-30ng/ml (50-75 nm) is insufficient, and less than 20ng/ml (50nM) is deficient.

06

What researchers measure

Primary outcomes

  1. pregnancy loss

    After a positive urinary hCG pregnancy test at home or clinically, there were no clinical signs of pregnancy on subsequent ultrasound or signs of pregnancy were lost after ultrasound confirmation.

    Time frame: Up to 28 weeks

Secondary outcomes

  1. Live birth

    A live baby born after 23 weeks of gestation

    Time frame: Up to 20 weeks

  2. Premature birth

    Delivery between 28 and 37 weeks gestation

    Time frame: 9 weeks

  3. Preeclampsia

    New hypertension (blood pressure greater than 140/90 mmHg) after 20 weeks of gestation combined with new unexplained urinary protein greater than or equal to 300mg/24h or a urinary protein/creatinine ratio greater than or equal to 0.3 or other conditions

    Time frame: 20 weeks

  4. Gestational diabetes mellitus

    Perform a 75-g OGTT with plasma glucose measurement when patient is fasting and at 1 and 2 h, at 24-to-28-wk gestation in women not previously diagnosed with overt diabetes The diagnosis of GDM is made when any one of the following plasma glucose values are met or exceeded: Fasting: 92 mg/dL 1. h: 180 mg/dL 2. h: 153 mg/dL

    Time frame: 4 weeks

  5. Fetal growth restriction

    Fetal weight below the 10th percentile of the mean weight for its gestational age or below 2 standard deviations of the mean weight

    Time frame: Up to 28 weeks

07

Study locations

1 of 1 sites recruiting
  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200127, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2023, 13 months after the start.

Of 61 non-industry observational studies under Vitamin D Deficiency, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 13 months is below that.

Counting every sponsor, half of 62 studies reached it within 19 months; a quarter within 9 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2023
First posted
Apr 24, 2023
StartActual
Nov 1, 2022
Primary completionEst.
Dec 31, 2023
CompletionEst.
Jan 31, 2024
Last update
Apr 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05824897
Lead sponsor
Aimin Zhao
Responsible party
Aimin Zhao (Chief physician, RenJi Hospital) — Sponsor-investigator
First posted
Apr 24, 2023
Start date
Nov 1, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Jan 31, 2024 (estimated)
Last update
Apr 24, 2023

Study contacts

Renyi Zhou
Contact
klyjzrysfmyn@163.com
86-15151561775
Aimin Zhao, MD
principal investigator · Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion